KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Sales

Inovio Pharmaceuticals (INO) FCF Margin (2016 - 2025)

Inovio Pharmaceuticals (INO) has disclosed FCF Margin for 16 consecutive years, with 41127.63% as the latest value for Q1 2025.

  • Quarterly FCF Margin changed N/A to 41127.63% in Q1 2025 from the year-ago period, while the trailing twelve-month figure was 136074.45% through Dec 2025, down 8805539.0% year-over-year, with the annual reading at 136074.45% for FY2025, 8805539.0% down from the prior year.
  • FCF Margin hit 41127.63% in Q1 2025 for Inovio Pharmaceuticals, down from 16807.62% in the prior quarter.
  • In the past five years, FCF Margin ranged from a high of 745.04% in Q3 2022 to a low of 41127.63% in Q1 2025.
  • Historically, FCF Margin has averaged 19733.86% across 5 years, with a median of 16807.62% in 2024.
  • Biggest YoY gain for FCF Margin was 2242629bps in 2022; the steepest drop was -2405518bps in 2022.
  • Year by year, FCF Margin stood at 4536.55% in 2021, then tumbled by -530bps to 28591.73% in 2022, then rose by 10bps to 25597.2% in 2023, then surged by 34bps to 16807.62% in 2024, then crashed by -145bps to 41127.63% in 2025.
  • Business Quant data shows FCF Margin for INO at 41127.63% in Q1 2025, 16807.62% in Q4 2024, and 28040.54% in Q2 2024.